PT  - JOURNAL ARTICLE
AU  - Aleksandra Milewska
AU  - Ying Chi
AU  - Artur Szczepanski
AU  - Emilia Barreto-Duran
AU  - Kevin Liu
AU  - Dan Liu
AU  - Xiling Guo
AU  - Yiyue Ge
AU  - Jingxin Li
AU  - Lunbiao Cui
AU  - Marek Ochman
AU  - Maciej Urlik
AU  - Sylwia Rodziewicz-Motowidlo
AU  - Fengcai Zhu
AU  - Krzysztof Szczubialka
AU  - Maria Nowakowska
AU  - Krzysztof Pyrc
TI  - HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV
AID  - 10.1101/2020.03.29.014183
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.03.29.014183
4099  - http://biorxiv.org/content/early/2020/03/31/2020.03.29.014183.short
4100  - http://biorxiv.org/content/early/2020/03/31/2020.03.29.014183.full
AB  - The beginning of 2020 brought us information about the novel coronavirus emerging in China. Rapid research resulted in the characterization of the pathogen, which appeared to be a member of the SARS-like cluster, commonly seen in bats. Despite the global and local efforts, the virus escaped the healthcare measures and rapidly spread in China and later globally, officially causing a pandemic and global crisis in March 2020. At present, different scenarios are being written to contain the virus, but the development of novel anticoronavirals for all highly pathogenic coronaviruses remains the major challenge. Here, we describe the antiviral activity of previously developed by us HTCC compound (N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride), which may be used as potential inhibitor of currently circulating highly pathogenic coronaviruses – SARS-CoV-2 and MERS-CoV.